Status
Conditions
Treatments
About
Intervention to promote cancer screenings among deaf, deafblind, and hard of hearing participants who have not received screening within the recommended guideline.
Full description
Study hypothesizes that the intervention that involves utilization of a DDBHH CHN will result in (i) DDBHH patients demonstrating greater adherence to screening compared to DDBHH patients who were assigned to the standard of care group , and (ii) higher patient-physician communication rating by DDBHH patients compared to DDBHH patients who were assigned to the standard of care group. Bilingual ASL-English measures (e.g., sociodemographics, cancer knowledge, patient-physician communication) will be administered to the participant at baseline data collection and again after the final data collection or by 11 months for comparison.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3, Lifestyle Considerations) and availability for the duration of the study
Male or female at birth age 45-80yo or female at birth age 45-80yo; age-eligible according to screening criteria
Self-reported diagnosis of bilateral hearing loss at birth or prior to 13 years old (defined as "early deafness") and use ASL
Willingness to adhere to the CHN clinical trial regimen
Willingness to provide cancer screening verification documentation; this will be reviewed during the informed consent procedure
Access to necessary resources to support video-based communication
Non-adherent to one or more cancer screening guidelines for breast, lung, prostate, colon, cervical cancers will be those who reported not having had the appropriate recommended screenings within the past year to cancer screening questions in the HINTS-ASL survey
Exclusion criteria
Younger or older than the age cutoff for the recommended cancer screening
Not capable of independently conducting the activities of daily living
In compliance with age- or risk-specific screening at the time of evaluation for study eligibility
Are currently undergoing cancer treatment or being evaluated for the presence of cancer at the time of evaluation for study eligibility
Will be engaged in more than 21 consecutive days of travel during the eleven-month study window
Knows other participants at baseline
Primary purpose
Allocation
Interventional model
Masking
200 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal